Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications

Data on the impact of COVID‐19 in chronic heart failure (CHF) patients and its potential to trigger acute heart failure (AHF) are lacking. The aim of this work was to study characteristics, cardiovascular outcomes and mortality in patients with confirmed COVID‐19 infection and a prior diagnosis of heart failure (HF). Further aims included the identification of predictors and prognostic implications for AHF decompensation during hospital admission and the determination of a potential correlation between the withdrawal of HF guideline‐directed medical therapy (GDMT) and worse outcomes during hospitalization.

[1]  Eike Nagel,et al.  Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[2]  J. Q. Brown,et al.  Unexpected Features of Cardiac Pathology in COVID-19 Infection. , 2020, Circulation.

[3]  A. Cohen,et al.  Pulmonary embolism in COVID-19 patients: a French multicentre cohort study , 2020, European heart journal.

[4]  J. L. Merino,et al.  Complicaciones arteriales trombóticas en pacientes hospitalizados con COVID-19 , 2020, Revista Española de Cardiología.

[5]  P. Serruys,et al.  Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study , 2020, European heart journal.

[6]  Irfan Ahmed Rind,et al.  The impact of COVID‐19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic , 2020, European journal of heart failure.

[7]  P. Ponikowski,et al.  Management of heart failure patients with COVID‐19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology , 2020, European journal of heart failure.

[8]  J. López-Sendón,et al.  Arterial thrombotic complications in hospitalized patients with COVID-19 , 2020, Revista Española de Cardiología (English Edition).

[9]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[10]  C. Granger,et al.  Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial , 2020, American Heart Journal.

[11]  C. Specchia,et al.  Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy , 2020, European heart journal.

[12]  P. Emery,et al.  Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia , 2020, The Lancet Rheumatology.

[13]  G. Mancia,et al.  Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 , 2020, The New England journal of medicine.

[14]  A. Troxel,et al.  Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 , 2020, The New England journal of medicine.

[15]  Qingbo Xu,et al.  Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 , 2020, Circulation research.

[16]  G. Pontone,et al.  COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel , 2020, European heart journal cardiovascular Imaging.

[17]  Tao Guo,et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[18]  Ezekiel J Emanuel,et al.  Fair Allocation of Scarce Medical Resources in the Time of Covid-19. , 2020, The New England journal of medicine.

[19]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[20]  S. Solomon,et al.  Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC Heart Failure Position Paper. , 2020, JACC. Heart failure.

[21]  G. Filippatos,et al.  Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations , 2019, European journal of heart failure.

[22]  Deepak L. Bhatt,et al.  Effect of Influenza on Outcomes in Patients With Heart Failure. , 2019, JACC. Heart failure.

[23]  D. Pennell,et al.  Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial , 2019, The Lancet.

[24]  Akshay S. Desai,et al.  Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial , 2018, JAMA cardiology.

[25]  D. Levy,et al.  Response to Letter Regarding Article, "Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction". , 2016, Circulation.

[26]  D. Levy,et al.  Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. , 2016, Circulation.

[27]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[28]  Piotr Ponikowski,et al.  EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot) , 2013, European journal of heart failure.

[29]  D. Musher,et al.  Acute pneumonia and the cardiovascular system , 2013, The Lancet.

[30]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[31]  Gregory W. Rose,et al.  Cardiac Complications in Patients with Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Observational Studies , 2011, PLoS medicine.